# ULTRAGENYX PHARMACEUTICAL IN (RARE)

> Institutional ownership reported to the SEC as of Q3 2026, from Form 13F filings. Source: https://holderbook.com/stocks/RARE/

- Reporting holders: 4
- Reported value: $54.8K
- Held through calls: 0.0%
- Held through puts: 0.0%

A 13F reports long US equity positions only. Shorts, bonds, foreign listings and cash are not visible here, and positions are disclosed up to 45 days after the quarter ends.

## Largest holders

| Manager | Value | Shares | Share of their book | Quarters held |
|---|---|---|---|---|
| [Versant Capital Management, Inc](https://holderbook.com/funds/1735057-versant-capital-management-inc/) | $38.4K | 2,556 | 0.0% | 10 |
| [MassMutual Private Wealth & Trust, FSB](https://holderbook.com/funds/1103653-massmutual-private-wealth-trust-fsb/) | $10.4K | 695 | 0.0% | 13 |
| [GAMMA Investing LLC](https://holderbook.com/funds/2010235-gamma-investing-llc/) | $5.1K | 341 | 0.0% | 12 |
| [Farther Finance Advisors, LLC](https://holderbook.com/funds/1992825-farther-finance-advisors-llc/) | $812 | 54 | 0.0% | 7 |

## Quarter by quarter

| Quarter | Holders | Reported value |
|---|---|---|
| Q3 2026 | 4 | $54.8K |
| Q2 2026 | 318 | $4.0B |
| Q1 2026 | 296 | $2.1B |
| Q4 2025 | 296 | $2.3B |
| Q3 2025 | 312 | $3.1B |
| Q2 2025 | 317 | $3.7B |
| Q1 2025 | 306 | $3.3B |
| Q4 2024 | 318 | $3.8B |
| Q3 2024 | 306 | $4.9B |
| Q2 2024 | 274 | $3.7B |
| Q1 2024 | 274 | $3.8B |
| Q4 2023 | 241 | $4.0B |